Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
not pregnant or breastfeeding, and not planning to become pregnant during the study
history of symptoms of persistent asthma for at least one year
current use of acceptable asthma treatments and willingness to taper or discontinue these treatments; acceptable asthma treatments:
* use of inhaled SABAs (e.g., albuterol/salbutamol) only "as-needed" with no use of asthma controller medications; OR
* use of stable doses of low- or medium-dose inhaled corticosteroids (ICS), alone, or in combination with either a long-acting beta-agonist (LABA) or other asthma controller medications (including leukotriene receptor antagonists) and can tolerate tapering or discontinuation
no history of smoking OR no smoking within \<1 year with a smoking history of ≤10 pack-years
ability to maintain a constant day/night, awake/sleep cycle
agreement to not change habitual consumption of beverages or food containing caffeine throughout the study
Body Mass Index (BMI) of 15 to 40 kg/m\^2
You may not be if
myocardial infarction, congestive heart failure, or uncontrolled cardiac arrhythmia within past ≤3 months
hospitalization within past ≤4 weeks
major surgical procedure within past ≤4 weeks
participation in a clinical study involving an investigational drug within past ≤4 weeks
current regular use or recent (within past ≤5 years) past abuse of alcohol (\>14 drinks/week) or illicit drugs
donation of a unit of blood within past ≤2 weeks or intention to donate a unit of blood during the study
evidence of another clinically significant, active pulmonary disorder such as chronic obstructive pulmonary disease (COPD)
emergency room treatment for asthma within past ≤4 weeks or hospitalization for asthma within past ≤8 weeks
respiratory tract infection requiring antibiotic treatment within past ≤8 weeks
evidence of active, clinically significant sinus disease within past ≤1 week
history of a clinically significant psychiatric disorder, other than stable depression, within past ≤12 weeks
history of HIV
hypersensitivity or intolerance to inhaled beta-agonists, leukotriene antagonists, leukotriene synthesis inhibitors, or any of their ingredients, including lactose and galactose
clinically unstable disease of the ophthalmologic, neurological, hepatic, renal, connective tissue, genitourinary, gastrointestinal, cardiovascular or hematologic systems
current cancer or history (within past ≤5 years) of cancer (except for successfully treated basal and squamous cell carcinomas of the skin); if cancer-free for \>5 years, study participation may be allowed
evidence of uncontrolled hypertension
Clareo Health | A Dose-Ranging Study of MK-1029 in Adults With Persistent Asthma (MK-1029-012)
